Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $21.1K | $71.4K | $228K | $4.35M | $24.1M | $34.9M | $36.3M |
| Revenue growth | — | — | — | — | 238.1% | 219.9% | 1802.4% | 454.4% | 44.7% | 4.1% |
| Gross profit | — | $0.00 | $0.00 | $10.1K | $45.6K | $111K | $1.70M | $8.34M | $10.7M | $12.3M |
| Gross margin | — | — | — | 47.7% | 63.8% | 48.4% | 39.0% | 34.6% | 30.6% | 33.8% |
| Operating income | -$993K | -$857K | -$1.16M | -$642K | -$577K | -$2.44M | -$27.0M | -$4.79M | -$5.81M | -$6.23M |
| Operating margin | — | — | — | -3037.9% | -807.8% | -1068.2% | -621.3% | -19.9% | -16.7% | -17.2% |
| Net income | -$3.50M | -$1.04M | -$2.16M | -$1.66M | -$2.78M | -$12.4M | -$26.7M | -$4.51M | -$5.13M | -$5.98M |
| Net margin | — | — | — | -7860.9% | -3898.7% | -5444.4% | -615.4% | -18.7% | -14.7% | -16.5% |
| EPS (diluted) | — | — | — | — | — | -$4.76 | -$1.76 | -$351.36 | -$7.32 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$314K | -$544K | -$513K | -$496K | -$657K | -$1.83M | -$5.25M | -$8.78M | -$12.5M | -$5.33M |
| Capital expenditures | $3.44K | $3.72K | $18.9K | $860.00 | $1.19K | $0.00 | $194K | $82.3K | $1.66M | $174K |
| Free cash flow | -$318K | -$547K | -$532K | -$497K | -$658K | -$1.83M | -$5.44M | -$8.86M | -$14.2M | -$5.51M |
| Share buybacks | — | — | — | — | — | — | — | $541K | $3.14M | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $57.5K | $108K | $111K | $40.5K | $990K | $2.05M | $21.8M | $16.3M | $9.69M | $9.12M |
| Total assets | $64.4K | $257K | $1.15M | $98.1K | $1.05M | $2.20M | $29.2M | $27.3M | $30.6M | $30.1M |
| Total liabilities | $274K | $831K | $1.20M | $834K | $2.00M | $1.99M | $7.62M | $6.14M | $7.06M | $7.04M |
| Shareholders' equity | -$210K | -$573K | -$55.8K | -$735K | -$955K | $212K | $21.6M | $21.2M | $23.5M | $23.0M |
| Retained earnings | -$12.6M | -$13.6M | -$15.8M | -$17.4M | -$20.2M | -$32.7M | -$59.4M | -$63.9M | -$69.0M | -$75.0M |
| Shares (wtd avg diluted) | 425M | 43.6M | 3.05M | 10.9M | 1.02M | 2.61M | 15.2M | 12.8B | 702K | 4.16M |
Every figure is extracted from Sunshine Biopharma Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.